KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Other Accumulated Expenses: 2018-2023

Historic Other Accumulated Expenses for Esperion Therapeutics (ESPR) over the last 3 years, with Dec 2023 value amounting to $25.0 million.

  • Esperion Therapeutics' Other Accumulated Expenses rose 89.32% to $25.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was $25.0 million, marking a year-over-year increase of 89.32%. This contributed to the annual value of $25.0 million for FY2023, which is 89.32% up from last year.
  • Per Esperion Therapeutics' latest filing, its Other Accumulated Expenses stood at $25.0 million for Q4 2023, which was up 89.32% from $13.2 million recorded in Q4 2022.
  • In the past 5 years, Esperion Therapeutics' Other Accumulated Expenses registered a high of $30.4 million during Q4 2021, and its lowest value of $3.2 million during Q1 2020.
  • In the last 3 years, Esperion Therapeutics' Other Accumulated Expenses had a median value of $25.0 million in 2023 and averaged $22.9 million.
  • As far as peak fluctuations go, Esperion Therapeutics' Other Accumulated Expenses surged by 249.04% in 2019, and later plummeted by 56.58% in 2022.
  • Over the past 5 years, Esperion Therapeutics' Other Accumulated Expenses (Quarterly) stood at $11.9 million in 2019, then spiked by 108.83% to $24.8 million in 2020, then increased by 22.67% to $30.4 million in 2021, then tumbled by 56.58% to $13.2 million in 2022, then surged by 89.32% to $25.0 million in 2023.
  • Its Other Accumulated Expenses stands at $25.0 million for Q4 2023, versus $13.2 million for Q4 2022 and $30.4 million for Q4 2021.